AstraZeneca Clinical Setbacks Add To Pipeline Woes

AstraZeneca is terminating development of two Phase III clinical trial programs after they failed to meet their primary endpoints, dealing a blow to the U.K. drug maker's already troubled pipeline

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet